Dr. Jeffrey Parvin has a research program focused on the process of gene expression and on the molecular genetics of breast cancer. Dr. Parvin's training included receiving an MD and a PhD from Mt. Sinai School of Medicine (now called the Icahn School of Medicine) in microbiology for studies of the biochemistry of influenza virus expression. For his PhD work in the laboratory of Dr. Peter Palese, Jeff Parvin studied the evolution of the influenza virus and developed the first robust in vitro transcription system for the influenza viral RNA-dependent RNA polymerase on a synthetic RNA template. Dr. Parvin trained at the MIT Center for Cancer Research (now called the Koch Institute for Integrative Cancer Research) in the laboratory of Dr. Phillip Sharp. At MIT, Dr. Parvin characterized the biochemical requirements of RNA transcription on DNA templates with focus on how the topology of the DNA affected the RNA synthesis reaction. In his first academic appointment, Dr. Parvin was a faculty member at the Harvard School of Medicine and the Brigham & Women's Hospital. At Harvard, Dr. Parvin established a successful research program with multiple NIH and American Cancer Society Awards with a major focus on BRCA1 and breast cancer. In 2007, Dr. Parvin joined The Ohio State University Comprehensive Cancer Center (OSUCCC) and department of Biomedical Informatics where he now leads a research group focused on gene expression control, DNA repair, and breast cancer with expertise that spans biochemistry to cell biology to systems biology. Dr. Parvin holds multiple administrative positions in addition to his research: he was twice the interim-chair of the Biomedical Informatics Department, he is Director of the predoctoral Biomedical Sciences Graduate Program, and he is Associate Dean for Graduate Studies.